PA
AVXL icon

Parallel Advisors’s Anavex Life Sciences AVXL Stock Holding History

Parallel Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$648 Sell
250
-394
-61% -$1.17K ﹤0.01% 3755
2026
Q1 		$1.98K Buy
644
+205
+47% +$888 ﹤0.01% 3378
2025
Q4 		$1.56K Sell
439
-260
-37% -$1.59K ﹤0.01% 3200
2025
Q3 		$6.22K Hold
699
– – ﹤0.01% 2700
2025
Q2 		$6.45K Buy
699
+189
+37% +$1.61K ﹤0.01% 2650
2025
Q1 		$4.38K Hold
510
– – ﹤0.01% 2727
2024
Q4 		$5.48K Buy
510
+260
+104% +$2K ﹤0.01% 2607
2024
Q3 		$1.42K Hold
250
– – ﹤0.01% 2962
2024
Q2 		$1.05K Buy
+250
New +$1.01K ﹤0.01% 2942
2022
Q2 		– Sell
-17
Closed – – 2992
2022
Q1 		$0 Sell
17
-78
-82% -$959 ﹤0.01% 2965
2021
Q4 		$2K Buy
95
+16
+20% +$304 ﹤0.01% 2659
2021
Q3 		$1K Hold
79
– – ﹤0.01% 2803
2021
Q2 		$2K Buy
+79
New +$1.17K ﹤0.01% 2527
2017
Q2 		– Sell
-3,000
Closed -$17K – 2097
2017
Q1 		$17K Buy
+3,000
New +$15.5K ﹤0.01% 1011

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Parallel Advisors's AVXL Position: Q2 2026 in Review

Parallel Advisors reduced its Anavex Life Sciences (AVXL) stake by 61% in Q2 2026, selling an estimated $1.17K and leaving 250 shares worth $648. The position accounts for ﹤0.01% of the portfolio, ranked #3755.

Parallel Advisors first reported a position in AVXL in Q1 2017 and has held it in 14 quarters since. The position peaked at $17K in Q1 2017. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Parallel Advisors held 250 shares of Anavex Life Sciences worth $648 as of Q2 2026.
  • Parallel Advisors sold 394 Anavex Life Sciences shares in Q2 2026, an estimated $1.17K.
  • Anavex Life Sciences made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3755 holding.
  • Parallel Advisors first reported a position in Anavex Life Sciences in Q1 2017 and has held it in 14 quarters since.
  • Parallel Advisors's Anavex Life Sciences position peaked at $17K in Q1 2017.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.